| Balance Sheet Information |
2. Balance Sheet Information
Cash, Cash Equivalents and Restricted Cash
A summary of cash and cash equivalents and restricted cash is as follows:
|
|
|
|
|
|
|
|
|
June 30, 2022 |
|
|
|
|
|
(unaudited) |
|
December 31, 2021 |
Cash and Cash Equivalents |
|
$ |
2,427,902 |
|
$ |
7,854,690 |
Restricted Cash, Non-current |
|
|
49,307 |
|
|
45,000 |
Total Cash, Cash Equivalents and Restricted Cash |
|
$ |
2,477,209 |
|
$ |
7,899,690 |
Non-current restricted cash consists of deposits with financial institutions for corporate credit cards.
Prepaid Expenses
Prepaid expenses consist of the following:
|
|
|
|
|
|
|
|
|
June 30, 2022 |
|
|
|
|
|
(unaudited) |
|
December 31, 2021 |
Research and Development |
|
$ |
1,117,475 |
|
$ |
319,208 |
Insurance |
|
|
109,439 |
|
|
130,765 |
Other |
|
|
172,276 |
|
|
156,547 |
Total Prepaid Expenses |
|
$ |
1,399,190 |
|
$ |
606,520 |
Accrued Expenses
Accrued expenses consist of the following:
|
|
|
|
|
|
|
|
|
June 30, 2022 |
|
|
|
|
|
(unaudited) |
|
December 31, 2021 |
Executive Severance |
|
$ |
896,524 |
|
$ |
200,605 |
Payroll and Benefits |
|
|
362,736 |
|
|
737,365 |
Professional Fees |
|
|
313,853 |
|
|
194,425 |
Clinical Trials |
|
|
58,287 |
|
|
168,785 |
Other |
|
|
— |
|
|
28,961 |
Total Accrued Expenses |
|
$ |
1,631,400 |
|
$ |
1,330,141 |
|